Chemokines are increasingly recognised as playing a role in depression. Here we meta-analyse the data on concentrations of all chemokines in patients diagnosed with a major depression versus healthy controls. We included studies which utilised Diagnostic and Statistical Manual (DSM)-IV diagnostic criteria for major depression, participants free from major medical conditions, studies with healthy controls, and unstimulated measurements of chemokines. We only included chemokines which had ≥3 studies performed. Two chemokines and 15 studies in total met criteria for this meta-analysis; 8 for Monocyte Chemotactic Protein (MCP)-1/CCL2 (n = 747), and 7 for Interleukin (IL)-8/CXCL8 (n = 560). There were significantly higher concentrations of CCL2/MCP-1 in depressed subjects compared with control subjects -overall mean difference of 36.43 pg/mL (95% CI: 2.43 to 70.42). There was significant heterogeneity across these studies (I2 = 98.5%). The estimates of mean difference between the control and depression groups did not remain significant when the trim-and-fill procedure was used to correct for publication bias. There was no significant difference in concentrations of IL-8/CXCL8 in depressed subjects compared with control subjects. Significant heterogeneity was found across these studies (I2 = 96.7%). The estimates of mean difference between the control and depression groups remained non-significant when the trim-and-fill procedure was used to correct for publication bias. This metaanalysis reports significantly heterogeneity in this field among studies. There are higher concentrations of the chemokine MCP-1/CCL2 in depressed subjects compared with control subjects, and no differences for IL-8/ CXCL8. More high quality research and consistent methodologies are needed in this important area of enquiry.
Introduction
Novel diagnostic and treatment strategies for depression are urgently needed. Recent global data suggests unipolar depression currently ranks 11th for disability adjusted life years, a 37% increase since 1990 (Murray et al., 2012) . The burden is expected to continue to grow into the 21st century (Holtzheimer et al., 2008; Murray et al., 2012) . Hence, this is an unprecedented burden of depressive illness requiring increased effort to find novel therapeutic agents for treatment (Licinio, 2011) .
In the field of psychiatric immunology, much of the focus on the role of the immune system in depression has been placed on the innate immune response and inflammation. Innate immune cytokines such as tumour necrosis factor (TNF)-α, interleukin (IL)-1β, IL-6 and interferon (IFN)-γ have been repeatedly shown to exert effects on key processes such as neuroplasticity, neurotransmission, oxidative stress and neuroendocrinological functions that are considered to be central to the development of depression (Dantzer et al., 2008; Eyre and Baune, 2012; Haroon et al., 2012; McAfoose and Baune, 2009; Miller et al., 2009 ). The seminal meta-analysis (Dowlati et al., 2010) of 24 studies found significantly higher concentrations of the proinflammatory cytokines, TNFalpha and IL-6, in depressed subjects compared with control subjects. An updated meta-analysis (Haapakoski et al., 2015) of IL-6, C-reactive protein and TNF-α found higher levels of IL-6 and CRP in depressed patients versus controls (29 studies for IL-6 and 20 for CRP). These studies strengthen evidence that depression is accompanied by activation of the inflammatory response system (Dowlati et al., 2010 ).
An involvement of immune factors in the pathophysiology of depression is now considered to be far greater than that of only the innate immune system, inflammation and glia (Eyre et al., 2015) . Indeed, a complex interaction is suspected to occur in the CNS between parts of the innate and adaptive immune system (Ransohoff and Brown, 2012) . For example, chemokines are increasingly believed to be involved in depression pathophysiology, likely through neuromodulatory and neurotransmitter-like effects, as well as 
